Technology | October 19, 2008

FISH Offers Introducer Sheath, Closure in One Device

Morris Innovative offers the FISH (Femoral Introducer Sheath and Hemostasis) Device that combines one sheath as both an introducer and closure device.

The FISH utilizes a sleeve of extracellular matrix, known as small intestinal submucosa (SIS), pre-mounted on a sheath introducer to serve as the closure mechanism. The SIS is remodeled into native arterial wall tissue in about 30 days, the company said. Instead of the formation of scar tissue, viable host tissue is formed at the arteriotomy with the use of the FISH device. The company said this allows easy reaccess during future procedures.

Because FISH uses a single introducer and hemostasis sheath, the time for deployment and the time required in the catheterization lab at the conclusion of the diagnostic or interventional procedure should be dramatically reduced, the manufacturer said.

Follow up interviews with patients participating in the clinical trial of the device indicated minimal patient discomfort. FISH works from inside the vessel, enhancing clotting mechanisms, while avoiding impingement and injury to the nerve tissue that resides on the external surface of and adjacent to the vessel. The clinical trials also showed significant reductions in time to hemostasis and time to ambulation for the patients.

The complication rate of the device after 200 patients receiving the device is 0.5 percent. The company said this rate is among the lowest for this type of trial and can be attributed to the reversibility of the device, as well as the infection resistant properties of the SIS. In the event of a complication, FISH biomaterial can easily be removed by using the safety sutures, and administering manual compression to close the arterial opening.

The company launches the device in October 2008.

Related Content

Essential Medical Inc. received U.S. Food and Drug Administration (FDA) clearance for its large bore Manta Vascular Closure Device. It is designed to close large puncture sites in the femoral artery from larger sized transcatheter devices, including the Impella heart pump, endovascular stent grafts and transcatheter valves.
Technology | Vascular Closure Devices | April 03, 2019
April 3, 2019 — Essential Medical Inc. received U.S.
FDA Approves Vascade MVP Vascular Closure System
Technology | Vascular Closure Devices | December 20, 2018
Cardiva Medical Inc. announced the company has received premarket approval (PMA) from the U.S. Food and Drug...
PerQseal Large Bore Closure Device Launches in Europe
News | Vascular Closure Devices | November 21, 2018
Vivasure Medical Ltd. recently announced the European launch of the PerQseal closure device for large-bore...
Vascade MVP Reduces Time to Ambulation Follow EP Procedures
News | Vascular Closure Devices | November 11, 2018
The Vascade MVP vascular closure system met its endpoints compared to manual compression in a pivotal clinical study...
Technology | Vascular Closure Devices | November 05, 2018
November 2, 2018 — Cordis, a Cardinal Health company, today announced the U.S.
Teleflex Acquires Essential Medical
News | Vascular Closure Devices | October 05, 2018
Teleflex Inc. announced the acquisition of Essential Medical Inc. Based in Exton, Pa., Essential Medical is a privately...
Cardiva Medical Announces Completion of the AMBULATE Pivotal Trial
News | Vascular Closure Devices | May 10, 2018
Cardiva Medical Inc. announced the completion of the AMBULATE pivotal trial, one of several clinical trials in the...
Cardiva Medical Announces $41 Million for AMBULATE Vascular Closure Device Trial
News | Vascular Closure Devices | February 21, 2018
Vascular closure device provider Cardiva Medical announced that the company has closed on $11 million in additional...
Overlay Init